Pelareorep Shows Immune Activation in Myeloma
Oncolytics Biotech reports translational data from a Phase 1b/2 trial of pelareorep in relapsed or refractory multiple myeloma patients.
Updated on Nov. 9, 2026 in Biotech

Oncolytics Biotech Inc. announced translational data from a Phase 1b/2 trial of pelareorep in patients with relapsed or refractory multiple myeloma. The analysis reports changes in myeloid cells, myeloma cells, and CD8 T cell populations in patients receiving pelareorep with bortezomib, dexamethasone, and pembrolizumab.
Why it matters
The findings point to immune changes associated with treatment response in a disease that often becomes resistant to standard therapies. The data are expected to support further evaluation of pelareorep alongside other immune-based treatments.
The analysis compares responding and non-responding patients, with responders showing greater expansion of CD8 effector memory T cells and lower levels of T cell exhaustion. Trial participants had a median of four prior lines of therapy, with a range of three to eleven.
The players
Oncolytics Biotech Inc.
A clinical-stage immunotherapy company developing pelareorep, an investigational intravenous treatment that targets tumor cells.
The details
Cohort 1 received bortezomib, dexamethasone, and pembrolizumab, while Cohort 2 added pelareorep to the same regimen. Pelareorep is an intravenously delivered, investigational immunotherapy that selectively replicates in tumor cells and activates innate and adaptive anti-tumor responses.
Timeline
November 9, 2026: Oncolytics announced the translational data.
December 12, 2026: Poster presentation at the 68th ASH Annual Meeting.
Biotech Pipeline
The poster presentation at the 68th ASH Annual Meeting places the pelareorep translational data before hematology researchers, a venue where early-stage myeloma immunotherapy findings are typically reviewed. The data extend immune-based approaches for relapsed or refractory multiple myeloma.
For patients with relapsed or refractory multiple myeloma, this research is at a translational stage and does not yet change available treatment options. The findings may inform future clinical trials that combine immune-based therapies with standard regimens.
The takeaway
Immune changes in CD8 T cells may help distinguish patients who respond to combination therapy from those who do not. Watch for the full poster data at the ASH meeting to see how these findings develop.
What happens next
Oncolytics will present the single-cell analysis as a poster at the 68th ASH Annual Meeting on December 12, 2026.
Further reading
Explore more Biotech developments shaping drug development in the United States.






